SCHEMBL3753473

SCHEMBL3753473

FC(F)(F)c1ccc(C#Cc2ccc(C(S)=C(S)c3ccc(C#Cc4ccc(C(F)(F)F)cc4)cc3)cc2)cc1.FC(F)(F)c1ccc(C#Cc2ccc(C(S)=C(S)c3ccc(C#Cc4ccc(C(F)(F)F)cc4)cc3)cc2)cc1.[Ni]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.45
CES1 P23141 2/20 0.45
KIF11 P52732 2/20 0.41
RARB P10826 2/20 0.41
RARG P13631 2/20 0.41
SRD5A2 P31213 1/20 0.40
GSK3B P49841 2/20 0.39
PTPN1 P18031 2/20 0.39
ORAI1 Q96D31 1/20 0.36
ORAI2 Q96SN7 1/20 0.36
ORAI3 Q9BRQ5 1/20 0.36
TRPV6 Q9H1D0 1/20 0.36
RARA P10276 1/20 0.36
MGLL Q99685 1/20 0.36
NR4A1 P22736 1/20 0.36
NR4A2 P43354 1/20 0.36
NR4A3 Q92570 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763045 0.88 CES2 (0.56) CES2CES1KIF11SRD5A2GSK3B
SCHEMBL14998069 0.81 KIF11 (0.56) CES2CES1KIF11ORAI1ORAI2
SCHEMBL16747679 0.81 KIF11 (0.56) CES2CES1KIF11ORAI1ORAI2
SCHEMBL3753543 0.78 CES2 (0.76) CES2CES1KIF11RARBRARG
SCHEMBL22721378 0.77 SRD5A2 (0.69) CES2CES1RARBRARGSRD5A2
SCHEMBL22721407 0.76 MAOB (0.58) CES2CES1RARBRARGSRD5A2
SCHEMBL672493 0.75 KIF11 (0.64) CES2CES1KIF11ORAI1ORAI2
SCHEMBL3756688 0.75 APP (0.55)
SCHEMBL12669342 0.75 KIF11 (0.64) CES2CES1KIF11ORAI1ORAI2
SCHEMBL31055613 0.73 CES2 (0.45) CES2CES1KIF11RARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842830-B2 Transition-metal charge-transport materials, methods of fabrication thereof, and methods of use thereof GEORGIA TECH RESEARCH CORPORATION (US) 2010-11-30 US disclosed
US-20080121870-A1 Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof GEORGIA TECH RESEACH CORPORATION 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080121870-A1 Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof SLC39A3, SLC6A6, SLC6A9 CES2 1387/4885CES1 4295/4885KIF11 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.